Literature DB >> 22623044

Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Stephanie J Wallace1, Jian Li, Roger L Nation, Richard J Prankerd, Ben J Boyd.   

Abstract

Interaction of colistin and colistin methanesulfonate (CMS) with liposomes has been studied with the view to understanding the limitations to the use of liposomes as a more effective delivery system for pulmonary inhalation of this important class of antibiotic. Thus, in this study, liposomes containing colistin or CMS were prepared and characterized with respect to colloidal behavior and drug encapsulation and release. Association of anionic CMS with liposomes induced negative charge on the particles. However, degradation of the CMS to form cationic colistin over time was directly correlated with charge reversal and particle aggregation. The rate of degradation of CMS was significantly more rapid when associated with the liposome bilayer than when compared with the same concentration in aqueous solution. Colistin liposomes carried positive charge and were stable. Encapsulation efficiency for colistin was approximately 50%, decreasing with increasing concentration of colistin. Colistin was rapidly released from liposomes on dilution. Although the studies indicate limited utility of colistin or CMS liposomes for long duration controlled-release applications, colistin liposomes were highly stable and may present a potential opportunity for coformulation of colistin with a second antibiotic to colocalize the two drugs after pulmonary delivery.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623044      PMCID: PMC3437939          DOI: 10.1002/jps.23203

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  43 in total

1.  Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Andrea L H Kwa; ChinSiew Loh; Jenny G H Low; Asok Kurup; Vincent H Tam
Journal:  Clin Infect Dis       Date:  2005-07-20       Impact factor: 9.079

2.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

5.  Use of liposomes to deliver bactericides to bacterial biofilms.

Authors:  Malcolm N Jones
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

6.  Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Kingsley Coulthard; Robert W Milne; Craig R Rayner; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

7.  Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.

Authors:  Anastasia Antoniadou; Flora Kontopidou; Garifalia Poulakou; Evangelos Koratzanis; Irene Galani; Evangelos Papadomichelakis; Petros Kopterides; Maria Souli; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2007-02-16       Impact factor: 5.790

8.  Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Authors:  X Corbella; A Montero; M Pujol; M A Domínguez; J Ayats; M J Argerich; F Garrigosa; J Ariza; F Gudiol
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

9.  Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization.

Authors:  Stephanie J Wallace; Jian Li; Roger L Nation; Richard J Prankerd; Tony Velkov; Ben J Boyd
Journal:  J Phys Chem B       Date:  2010-04-15       Impact factor: 2.991

10.  Liposome-enabled synergistic interaction of antimicrobial agents.

Authors:  Raymond M Schiffelers; Gert Storm; Marian T ten Kate; Lorna E T Stearne-Cullen; Jan G den Hollander; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  J Liposome Res       Date:  2002 Feb-May       Impact factor: 3.648

View more
  9 in total

Review 1.  Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?

Authors:  Kamal Dua; Shakti D Shukla; Rakesh K Tekade; Philip M Hansbro
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

2.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

3.  Colistin causes profound morphological alteration but minimal cytoplasmic membrane perforation in populations of Escherichia coli and Pseudomonas aeruginosa.

Authors:  Noëlle H O'Driscoll; T P Tim Cushnie; Kerr H Matthews; Andrew J Lamb
Journal:  Arch Microbiol       Date:  2018-02-08       Impact factor: 2.552

Review 4.  Polymyxin Delivery Systems: Recent Advances and Challenges.

Authors:  Natallia V Dubashynskaya; Yury A Skorik
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-29

Review 5.  Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis.

Authors:  Cecilia Velino; Francesca Carella; Alessio Adamiano; Maurizio Sanguinetti; Alberto Vitali; Daniele Catalucci; Francesca Bugli; Michele Iafisco
Journal:  Front Bioeng Biotechnol       Date:  2019-12-17

6.  Enhanced Antimicrobial and Antibiofilm Effect of New Colistin-Loaded Human Albumin Nanoparticles.

Authors:  Sara Scutera; Monica Argenziano; Rosaria Sparti; Federica Bessone; Gabriele Bianco; Chiara Bastiancich; Carlotta Castagnoli; Maurizio Stella; Tiziana Musso; Roberta Cavalli
Journal:  Antibiotics (Basel)       Date:  2021-01-08

7.  Hybrid Nanoparticles and Composite Hydrogel Systems for Delivery of Peptide Antibiotics.

Authors:  Dmitrii Iudin; Marina Vasilieva; Elena Knyazeva; Viktor Korzhikov-Vlakh; Elena Demyanova; Antonina Lavrentieva; Yury Skorik; Evgenia Korzhikova-Vlakh
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

Review 8.  Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.

Authors:  Nhan Dai Thien Tram; Pui Lai Rachel Ee
Journal:  Antibiotics (Basel)       Date:  2017-07-04

9.  Polypeptide Self-Assembled Nanoparticles as Delivery Systems for Polymyxins B and E.

Authors:  Dmitrii Iudin; Natalia Zashikhina; Elena Demyanova; Viktor Korzhikov-Vlakh; Elena Shcherbakova; Roman Boroznjak; Irina Tarasenko; Natalya Zakharova; Antonina Lavrentieva; Yury Skorik; Evgenia Korzhikova-Vlakh
Journal:  Pharmaceutics       Date:  2020-09-11       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.